INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Instituto
University of Münster
Münster, AlemaniaPublicaciones en colaboración con investigadores/as de University of Münster (33)
2021
-
EPIdemiology of Surgery-Associated Acute Kidney Injury (EPIS-AKI): Study protocol for a multicentre, observational trial
BMJ Open, Vol. 11, Núm. 12
-
Multicenter Next-Generation Sequencing Studies between Theory and Practice: Harmonization of Data Analysis Using Real-World Myelodysplastic Syndrome Data
The Journal of molecular diagnostics : JMD, Vol. 23, Núm. 3, pp. 347-357
2019
-
Infectious stimuli promote malignant B-cell acute lymphoblastic leukemia in the absence of AID
Nature Communications, Vol. 10, Núm. 1
-
Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation
Haematologica, Vol. 104, Núm. 5, pp. 929-936
2018
-
Dermatomyositis panniculitis: a clinicopathological and immunohistochemical study of 18 cases
Journal of the European Academy of Dermatology and Venereology, Vol. 32, Núm. 8, pp. 1352-1359
-
Lmo2 expression defines tumor cell identity during T-cell leukemogenesis
EMBO Journal, Vol. 37, Núm. 14
-
Loss of Pax5 exploits sca1-BCR-ABLp190 susceptibility to confer the metabolic shift essential for pB-ALL
Cancer Research, Vol. 78, Núm. 10, pp. 2669-2679
2017
-
Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation
Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380
2016
2015
-
Infection exposure is a causal factor in B-cell precursor acute lymphoblastic leukemia as a result of Pax5-inherited susceptibility
Cancer Discovery, Vol. 5, Núm. 12, pp. 1328-1343
2013
-
Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma
Journal of Clinical Oncology, Vol. 31, Núm. 4, pp. 448-455
2011
-
Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: Analysis of the VISTA trial
British Journal of Haematology, Vol. 153, Núm. 2, pp. 212-221
-
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. Melphalan-prednisone in the phase III VISTA trial in multiple myeloma
European Journal of Haematology, Vol. 86, Núm. 5, pp. 372-384
-
Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma
Haematologica, Vol. 96, Núm. 2, pp. 238-244
-
Multiple myeloma treatment strategies with novel agents in 2011: A European perspective
Oncologist, Vol. 16, Núm. 4, pp. 388-403
-
Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: Subanalysis of the phase 3 VISTA study
European Journal of Haematology, Vol. 86, Núm. 1, pp. 23-31
-
Treatment of relapsed and refractory multiple myeloma in the era of novel agents
Cancer Treatment Reviews, Vol. 37, Núm. 4, pp. 266-283
2010
-
Current multiple myeloma treatment strategies with novel agents: A European perspective
Oncologist, Vol. 15, Núm. 1, pp. 6-25
-
Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: Analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone
Blood, Vol. 116, Núm. 19, pp. 3743-3750